DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

メニュー 戻る Innovative-Therapies-Precision-Medicine-and-Diagnostics

Innovative Therapies, Precision Medicine & Diagnostics

Innovative therapies (such as cell and gene therapies) and precision medicine approaches are both based on the use of complex technologies, and potentially even employ the use of different regulated product types (e.g. biologics & devices or in vitro diagnostics). These areas are experiencing rapid evolution: growing scientific insight and clinical evidence, led to the development of highly effective therapies not only in rare disease but also in development for more prevalent and chronic conditions.

As their development requires integration of complex technologies (either in manufacturing processes or molecular evaluation of disease biology), regulators, policy makers and payers are adapting their approaches to evolve. We have seen many changes globally in their approach - how does Europe compare?

Who is This Track Designed For?

Developers of innovative therapies (such as gene and cell therapies), precision medicines and diagnostics: global biologics and IVD regulators, policy makers, industry leaders, academics, patients, HTA bodies representatives and payers.

25101-175w

The online program is now available. Explore the rich content we offer across 10 thought leadership tracks. 

View Searchable Programme

Topic Leader

Claudia Dollins

Claudia Dollins

Vice President, Precision Medicines, Global Regulatory Affairs

GlaxoSmithKline, Collegeville

View Innovative Therapies, Precision Medicine & Diagnostics Sessions

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。